Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 4:17 AM
Ignite Modification Date:
2025-12-25 @ 4:17 AM
NCT ID:
NCT07134920
Eligibility Criteria:
Inclusion Criteria:
* Diagnosis of recurrent pregnancy loss, recurrent implantation failure, unexplained infertility or severe dysmenorrhea and a positive BCL6 test Receptivadx
* Underwent assisted reproductive technology (ART or IVF)
* Treated with norethinedrone acetate 5 mg daily for 6 and 8 weeks or two monthly injections of Depo Leuprolide Acetate 7.5mg rior to embryo transfer cycle
* Euploid embryo transfer cycle was initiated within 1 week of completion of suppression protocol
* Adequate clinical documentation available, including treatment protocol, BCL6 results, and pregnancy outcomes
* If Endometrial Receptivity Analysis (ERA) was performed, result must be "receptive"
* A minimum uterine lining of 7.5mm was documented by ultrasound prior to the initiation of progesterone
Exclusion Criteria:
* Use of both norethinedrone acetate and Depo Leuprolide Acetate in the same treatment cycle
* Incomplete ART or outcome data
* Gestational carrier or egg donor
* No prescribed adjuvant therapy (e.g., Lovenox, Neupogen, IVIG)
Healthy Volunteers:
False
Sex:
FEMALE
Study:
NCT07134920
Study Brief:
Protocol Section:
NCT07134920